NCT07638566
A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Stopped Withdrawn before enrolling Sponsor's reason: An alternative study design is under consideration.
- Enrollment target: estimated 6 to confirmed 0
- Eligibility criteria expanded, about 7 words
- Primary endpoints: details revised at 1 of 2 entries
- Study First Submitted
- Stopped: terminated, suspended or withdrawn
Endpoints
Primary
Empasiprubart serum concentrations as input for a population PK-driven analysis to determine the effect of age and body size on CL and Vd
Timeframe: Up to 8 weeks
Free and total C2 levels as input for PK/PD modeling analysis
Timeframe: Up to 8 weeks
Secondary (4)
Incidence of AEs, SAEs and AESIs
Empasiprubart serum concentrations over time
Percentage reductions from baseline of free and total C2 levels over time
Incidence of ADA and NAb against empasiprubart in serum
Arms and interventions
Empasiprubart IVExperimental
Participants will receive empasiprubart IV
Biologicals: Empasiprubart IV